Bausch Health reported a 10% increase in third-quarter 2026 revenue to $2.94 billion and net income attributable to the company rose to $436 million, up from $179 million a year earlier. Adjusted earnings per share surged 53% to $1.77, while adjusted EBITDA grew 32% to $1.3 billion, marking the fourteenth consecutive quarter of growth excluding Bausch + Lomb. The company generated strong cash flow, reducing net debt by over $500 million, and announced a $50 million share repurchase program to offset management equity dilution. Bausch Health raised its full-year 2026 revenue, adjusted EBITDA, and cash flow guidance, reflecting confidence in sustained operational performance and long-term value creation.
Bausch Health's third quarter 2026 results and guidance update provide context for market activity as of Oct 29, 2026 02:12 WIB. For readers following the health sector, here is Pluang's market snapshot: out of 150 priced US health stocks, 87 rose and 62 fell today. Notable movers include ALMS at USD 6.98 with a 5.12% increase, HIMS at USD 29.26 with a 4.80% rise and a strong buy order activity of 88%, and GSK at USD 48.52 down 4.75% but with 100% buy orders. The most notable figure is HIMS's 88% buy order activity on Pluang.
SpaceX reported a strong Q3 with revenue up 161% year-over-year to $14.6 billion and a net profit of $4.4 billion, reversing last year's loss. Starlink, its satellite internet service, grew revenue by nearly 70% to $5.2 billion and added 1.6 million ...
SPIE, a leading European multi-technical services provider, has signed an agreement to acquire a 76% stake in SAR ANLAGENBAU GmbH, a major electrical engineering and automation firm based in Austria and Germany. This acquisition will enhance SPIE's p...
SPIE, a European leader in energy and communication services, has agreed to acquire a 76% stake in SAR ANLAGENBAU GmbH, a key electrical engineering and automation firm in Austria and Germany. This acquisition will broaden SPIE's service portfolio in...
The global dermatological therapeutics market is projected to grow from about $43 billion in 2025 to $97 billion by 2034, with a compound annual growth rate of around 10%. This growth is fueled by increasing cases of acne, psoriasis, and other chroni...
Blockchain.com has launched TRX options trading, providing easier access to TRON's native token through its platform. This move expands the TRON ecosystem's reach by simplifying options trading for retail and institutional users worldwide. TRON, know...
